TABLE 3.
Univariate and multivariate Cox regression analyses of variables and 28 and 90 days outcomes after propensity score matching.
| Univariate | Multivariate | |||
|---|---|---|---|---|
| HR (95%CI) | p value | HR (95%CI) | p value | |
| 28 days outcome | ||||
| HE | 3.25 (1.66, 6.35) | 0.001 | ||
| Use of 5-HT3RAs | 0.17 (0.70, 0.41) | <0.001 | 0.10 (0.04, 0.26) | <0.001 |
| CRRT | 3.44 (1.65, 7.19) | 0.001 | 2.73 (1.21, 6.14) | 0.015 |
| MELD score | 1.10 (1.06, 1.14) | <0.001 | 1.11 (1.06, 1.16) | <0.001 |
| 90 days outcome | ||||
| HE | 2.81 (1.61, 4.89) | <0.001 | 1.95 (1.08, 3.54) | 0.028 |
| Hepatorenal syndrome | 2.36 (1.18, 4.72) | 0.015 | ||
| Use of 5-HT3RAs | 0.26 (0.14, 0.49) | <0.001 | 0.16 (0.08, 0.31) | <0.001 |
| CRRT | 2.89 (1.50, 5.54) | 0.001 | ||
| MELD score | 1.09 (1.06, 1.13) | <0.001 | 1.11 (1.07, 1.15) | <0.001 |
CI, confidence interval; CRRT, continuous renal replacement therapy; HE, hepatic encephalopathy; HR, hazard ratio; 5-HT3RA, 5-HT3 receptor antagonist; MELD score, Model For End-Stage Liver disease score.